Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IP6K1 | Q92551 | 2/20 | 0.34 |
| ▸ | AR | P10275 | 3/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.32 |
| ▸ | SLC5A7 | Q9GZV3 | 2/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | GLP1R | P43220 | 1/20 | 0.31 |
| ▸ | GCGR | P47871 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.30 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23717300 | 1.00 | IP6K1 (0.34) | IP6K1ARENPP2SLC5A7EPHX2 | |
| SCHEMBL23700499 | 0.96 | EPHX2 (0.34) | IP6K1EPHX2MEN1KMT2APDE4D | |
| SCHEMBL23700501 | 0.96 | EPHX2 (0.34) | IP6K1EPHX2MEN1KMT2APDE4D | |
| SCHEMBL23700502 | 0.96 | EPHX2 (0.34) | IP6K1EPHX2MEN1KMT2APDE4D | |
| SCHEMBL23674682 | 0.94 | GABRA5 (0.34) | IP6K1ARENPP2SLC5A7EPHX2 | |
| SCHEMBL23674683 | 0.94 | GABRA5 (0.34) | IP6K1ARENPP2SLC5A7EPHX2 | |
| SCHEMBL23674680 | 0.94 | GABRA5 (0.34) | IP6K1ARENPP2SLC5A7EPHX2 | |
| SCHEMBL23700642 | 0.92 | AR (0.33) | IP6K1ARSLC5A7EPHX2MEN1 | |
| SCHEMBL23700643 | 0.92 | AR (0.33) | IP6K1ARSLC5A7EPHX2MEN1 | |
| SCHEMBL23700496 | 0.91 | ENPP2 (0.33) | ENPP2SLC5A7EPHX2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11420976-B2 | Heterocyclic compounds as anti-viral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| US-20210238188-A1 | HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238188-A1 | HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS | VIP, ACE, FURIN | IP6K1 2601/4885AR 4623/4885ENPP2 518/4885 |
| US-11420976-B2 | Heterocyclic compounds as anti-viral agents | VIP, ACE, FURIN | IP6K1 2601/4885AR 4623/4885ENPP2 518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.